Meyka Pro banner
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) Stock Competitors & Peer Comparison

See (2315.HK) competitors and their performances in Stock Market.

2315.HKHKSE
HealthcareBiotechnology
HK$52.75
HK$0.95(1.83%)
Hong Kong Market is Open · 15:51

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2315.HKHK$53.00+5.05%21.5B145.01HK$0.37N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$191.50+3.18%258.3B86.58HK$2.21N/A
1801.HKHK$92.50+3.99%161B170.10HK$0.54N/A
2269.HKHK$38.26+3.46%158.5B29.94HK$1.28N/A
6990.HKHK$504.00+3.62%117.5B-249.87-HK$2.02N/A
9926.HKHK$93.35+5.66%85.9B-69.59-HK$1.34N/A
3347.HKHK$38.20+4.09%46.4B39.10HK$0.98+0.38%
6821.HKHK$121.00+3.24%43.7B39.67HK$3.05+1.24%
1530.HKHK$17.18+6.38%43B4.48HK$3.84+1.46%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2315.HK vs 4332.HK Comparison July 2026

2315.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2315.HK stands at 21.5B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2315.HK is priced at HK$53.00, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2315.HK currently has a P/E ratio of 145.01, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2315.HK's ROE is +0.11%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2315.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2315.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions